Back to search

Article

Efficacy and Safety of Azacitidine Plus Low-dose Dasatinib Maintenance Therapy for Patients with Intermediate and High-risk Acute Myeloid Leukemia: A Prospective, Randomized, Phase Ⅱ Clinical Trial

2026-07-03

Abstract excerpt

<title>Abstract</title> <p>Purpose Acute myeloid leukemia (AML) is a hematological malignancy with a high recurrence rate, particularly in intermediate and high-risk AML patients. Therefore, maintenance therapy is particularly important. Azacitidine (AZA) monotherapy maintenance can significantly improve the prognosis of AML patients. The second-generation tyrosine kinase inhibitors (TKIs) combined with demethyl...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
22ada7f8-2092-5fa9-9c68-10437753ad4f
DOI
10.21203/rs.3.rs-8993109/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Efficacy and Safety of Azacitidine Plus Low-dose Dasatinib Maintenance Therapy for Patients with Intermediate and High-risk Acute Myeloid Leukemia: A Prospective, Randomized, Phase Ⅱ Clinical TrialDOI 10.21203/rs.3.rs-8993109/v1
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patientsSemantic proximity
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First RemissionSemantic proximity
Maintenance therapy with Azacitidine for patients with myeloid malignancies after allogeneic hematopoietic stem cell transplantationSemantic proximity
A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612Semantic proximity
Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantationSemantic proximity
Safety and efficacy of venetoclax-azacitidine combined with low-dose idarubicin and cytarabine regimens for the treatment of newly diagnosed acute myeloid leukemia patients compared to the standard chemotherapy: a propensity score-matched real- world single-center experienceSemantic proximity
DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences.Semantic proximity
Emerging treatments in acute myeloid leukemia: current standards and unmet challenges.Semantic proximity
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AMLSemantic proximity
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.Semantic proximity
Phase II study of dual epigenetic targeting with chidamide and azacitidine in patients with high-risk acute myeloid leukemia after allo-HSCTSemantic proximity
Modified Azacitidine plus Cytarabine versus Traditional Cytarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia: A Retrospective and Propensity Score Matched AnalysisSemantic proximity
Select a neighboring publication to make it the new centre.